WHO ICTRP trial
Long term study of safety and efficacy of LCZ696 and LCZ696 combination with…
EUCTR2013-002306-31-ES · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2013-002306-31-ES |
|---|---|
| Public title | Long term study of safety and efficacy of LCZ696 and LCZ696 combination with amlodipine in patients with hypertension |
| Scientific title | An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with essential hypertension |
| Primary sponsor | Novartis Farmacéutica, S.A. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Panama;Philippines;Ecuador;Spain;Thailand;Guatemala;Colombia;Vietnam;Mexico;Argentina;Brazil;Dominican Republic;Peru;South Africa |
| Conditions | Essential hypertension MedDRA version: 16.1 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] |
| Interventions | Product Code: LCZ696 Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: 936623-90-4 Current Sponsor code: LCZ696 Other descriptive name: LCZ696 Concentration unit: mg milligram(s) Concentration type: equal Concentration number… |
| Registration date | Dec 11, 2013 |
| Target size | 600 |
| Secondary IDs | CLCZ696A2320E1 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: